HER2 Expression in Different Types of Thyroid Neoplasms Assessed by Two Immunohistochemical Scoring Systems: A 3-Year Follow-Up Study in a Referral University Hospital in Tehran, Iran
Archives of Men's Health,
Vol. 10 No. 1 (2026),
3 July 2026
,
Page e1
https://doi.org/10.22037/amh.v10i1.51539
Abstract
Introduction: Thyroid neoplasms are the most common endocrine malignancy; thus, it is important to introduce diagnostic and predictive factors for them. HER2, which is overexpressed in some other malignancies such as breast and gastrointestinal (GI) neoplasms, has been proposed as a diagnostic and prognostic factor. In this study, we investigated HER2 expression in different types of thyroid cancer. This study aimed to investigate the expression frequency of the human epidermal growth factor receptor 2 (HER2) in thyroid neoplasms, and its relationship with the type, stage, and prognosis of the malignancy. Material and Methods: We studied 91 patients who were referred to Taleghani Hospital, Tehran, Iran, and underwent thyroidectomy or thyroid lobectomy, in the years 2018 to 2021. Their medical records, hematoxylin and eosin (H&E)-stained slides, and paraffin-embedded blocks were extracted from the hospital pathology archive. The specimens underwent microtomy and were subjected to immunohistochemistry (IHC) for HER2 evaluation. After the interpretation, the data were statistically analyzed. Results: The only significant relationship was between HER2 expression (when interpreted based on the gastric scoring system) and age (P-value= 0.036). However, there was no significant relationship between HER2 expression and any of the other variables of our study. Conclusion: Despite HER2 being a prognostic factor in breast and GI neoplasms, our study suggests that HER2 expression has no such role in thyroid neoplasm cases, and is only positive in patients younger than 45 years old with thyroid malignancies (when interpreted based on the gastric scoring system).
- Thyroid Neoplasm
- Immunohistochemistry
- HER2 (Human Epidermal Growth Factor Receptor 2)
- DAKO Scoring Guideline
- Gastric Scoring System
How to Cite
References
1. Yang Y, Bai X, Lu J, Zou R, Ding R, Hua X. Assessment of five typical environmental endocrine disruptors and thyroid cancer risk: a meta-analysis. Front Endocrinol (Lausanne). 2023;14:1283087.
2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20(5):525-31.
3. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
4. Amaral M, Afonso RA, Gaspar MM, Reis CP. Anaplastic thyroid cancer: How far can we go? Excli j. 2020;19:800-12.
5. Hu J, Yuan IJ, Mirshahidi S, Simental A, Lee SC, Yuan X. Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy. Int J Mol Sci. 2021;22(4).
6. Giuffrida D, Scollo C, Pellegriti G, Lavenia G, Iurato MP, Pezzin V, et al. Differentiated thyroid cancer in children and adolescents. J Endocrinol Invest. 2002;25(1):18-24.
7. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6(4):292-306.
8. Solomon B, Rischin D. Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer. J Clin Oncol. 2012;30(2):119-21.
9. Mondi MM, Rich R, Ituarte P, Wong M, Bergman S, Clark OH, et al. HER2 expression in thyroid tumors. Am Surg. 2003;69(12):1100-3.
10. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12 Suppl 1:S3-8.
11. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, et al. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res. 2019;25(7):2033-41.
12. Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188549.
13. Sodergren SC, Copson E, White A, Efficace F, Sprangers M, Fitzsimmons D, et al. Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group. Target Oncol. 2016;11(3):277-92.
14. Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, et al. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch. 2003;442(4):322-8.
15. Freudenberg LS, Sheu S, Görges R, Mann K, Bokler S, Frilling A, et al. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin. 2005;44(5):179-82, 84.
16. Ruggeri RM, Campennì A, Giuffrè G, Giovanella L, Siracusa M, Simone A, et al. HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin. Int J Mol Sci. 2016;17(12).
17. Rabiee S, Nadoushan MJ, Rayeni NM, Ansari I. Correlation between human epidermal growth factor receptor 2 oncoprotein expression and some prognostic factors in papillary thyroid carcinoma. Indian J Pathol Microbiol. 2017;60(3):324-7.
18. Kim Y-S, Kim J-S, Kim Y-S. EGFR and HER2 Expression in Papillary Thyroid Carcinoma. Journal of Endocrine Surgery. 2018;18:228.
19. Siraj AK, Beg S, Jehan Z, Prabhakaran S, Al-Sobhi SS, Al-Dawish M, et al. The role of HER2 overexpression in Middle Eastern papillary thyroid cancer. Translational Cancer Research. 2017;6(2):366-73.
20. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016;22(19):4619-25.
21. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805.
22. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457(3):299-307.
- Abstract Viewed: 7 times
- pdf Downloaded: 1 times